Kinjal K. Shah - Infectious Diseases

Author Information

Kinjal K. Shah is affiliated with the Department of Infectious Diseases at Sterling Hospital in Ahmedabad, India. The affiliation indicates a strong connection to clinical practice and research in infectious diseases, suggesting a focus on both the medical and scientific aspects of the field.

Research Contributions

Kinjal K. Shah has made significant contributions to the fields of oncology, immunology, and infectious diseases. Notable works include studies on the regulation of WNT/Beta-Catenin signaling, T cell receptor signaling, and resistance mechanisms in leukemia such as dexamethasone resistance. Shah has also contributed to research on the safety and efficacy of Tocilizumab for treating severe SARS-CoV-2 pneumonia and has explored conditions like SARS-CoV-2 viral sepsis with meningoencephalitis. Additionally, Shah has investigated the expanding endemicity of human melioidosis in India and explored targeted therapies for T-cell acute lymphoblastic leukemia.

Aliases

Kinjal K. Shah is also known by several aliases, including K Shah, Kinjal Shah, K. K. Shah, and Kinjal K Shah. These variations are likely used across different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	5,231
H-Index	17
Total Paper Count	53

Publications:

Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling

DOI: 10.3389/fonc.2022.858782

Year: 2022

T cell receptor (TCR) signaling in health and disease

DOI: 10.1038/s41392-021-00823-w

Year: 2021

The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia

DOI: 10.1038/s41698-021-00148-5

Year: 2021

Footprints of human melioidosis in the north western Indian states, expanding endemicity in India.

DOI: 10.1016/j.ijmmb.2021.04.003

Year: 2021

SARS-CoV-2 Viral Sepsis with Meningoencephalitis.

DOI: 10.4103/ijmm.IJMM_20_291

Year: 2020

Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study

DOI: 10.4103/ijmm.IJMM_20_298

Year: 2020

Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study.

DOI: 10.4103/ijmm.IJMM_20_298

Year: 2020

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

DOI: 10.1182/blood-2019-129823

Year: 2019

MON-451 Growth Hormone Deficiency (GHD) over 4 Years after Mild Traumatic Brain Injury (mTBI) in Deployed Veterans: Interim Review

DOI: 10.1210/JS.2019-MON-451

Year: 2019

Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation

DOI: 10.1038/s41525-019-0082-y

Year: 2019

Is There a Vaccine for E. Coli?

Can Respiratory Symptoms Be Prevented?

What are Antimalarial Drugs?

Can Climate Change Influence Antibiotic Resistance?

How is Hepatitis B Diagnosed?

How Can Bacterial Infections Be Prevented?

What are the Treatment Options?

What Are Antimicrobial Stewardship Programs?

What is the Role of Genomics in Tracking Disease Outbreaks?

What is the Public Health Response?

Partnered Content Networks

Relevant Topics